![Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5bbcdc5c6576e0425042645222a1a433570d3e04/3-Table3-1.png)
Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar
![IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis](https://www.mdpi.com/ijms/ijms-20-01637/article_deploy/html/images/ijms-20-01637-g001.png)
IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
![A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. | Semantic Scholar A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/34fd32696f2b1472725b338fc204d29585f2fe93/5-Figure2-1.png)
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. | Semantic Scholar
![A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer - European Urology Oncology A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer - European Urology Oncology](https://euoncology.europeanurology.com/cms/asset/582a732d-abcf-418b-836b-aec1dc587797/gr1.jpg)
A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer - European Urology Oncology
![SciELO - Brasil - Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and SciELO - Brasil - Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and](https://minio.scielo.br/documentstore/1677-6119/5GWVS9m8y55TZvZ89YVmVbz/e3f287786901ff1f9230b1df00909c7c5795c03c.gif)
SciELO - Brasil - Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and
![IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis](https://pub.mdpi-res.com/ijms/ijms-20-01637/article_deploy/html/images/ijms-20-01637-g001-550.jpg?1571315946)
IJMS | Free Full-Text | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
![Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-77668-w/MediaObjects/41598_2020_77668_Fig1_HTML.png)
Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports
![Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers](https://img.medscapestatic.com/pi/meds/ckb/07/23507tn.jpg)
Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers
![A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc](https://www.urotoday.com/images/stories/Beyond_the_Abstract/bta_zhu_fig1a.jpg)
A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc
![The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy - European Urology Focus The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/3cb767c3-7389-4858-8942-56d1d72f27fe/gr1.jpg)
The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy - European Urology Focus
![A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-43427-9/MediaObjects/41598_2019_43427_Fig1_HTML.png)